Cambridge Investment Research Advisors, Inc. Ocugen, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

  • $29.4 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 26, 2024
BUY
$1.18 - $1.98 $13,322 - $22,354
11,290 New
11,290 $17,000
Q3 2022

Oct 17, 2022
BUY
$1.75 - $3.1 $229 - $406
131 Added 0.77%
17,167 $30,000
Q2 2022

Jul 13, 2022
BUY
$1.83 - $3.45 $1,830 - $3,450
1,000 Added 6.24%
17,036 $38,000
Q1 2022

May 12, 2022
BUY
$2.34 - $4.72 $3,042 - $6,136
1,300 Added 8.82%
16,036 $52,000
Q4 2021

Feb 03, 2022
SELL
$4.38 - $15.67 $8,256 - $29,537
-1,885 Reduced 11.34%
14,736 $67,000
Q3 2021

Nov 02, 2021
BUY
$6.36 - $8.51 $105,709 - $141,444
16,621 New
16,621 $119,000

Others Institutions Holding OCGN

# of Institutions
124
Shares Held
78.3M
Call Options Held
535K
Put Options Held
523K
View Full List

About Ocugen, Inc.

OCGN Quotes by TradingView
  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $167M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email